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Abstract 
Inspired by the high antituberculous activity of novel nitro-substituted derivatives and based 
on promising predicted ADMET properties we have synthesized a series of 33 salicylanilides 
containing nitro-group in their salicylic part and evaluated them for their in vitro 
antimycobacterial, antimicrobial and antifungal activities. The presence of nitro-group in 
position 4 of the salicylic acid was found to be beneficial and the resulting molecules 
exhibited minimum inhibitory concentrations (MICs) ranging from 2 to 32 μM against 
Mycobacterium tuberculosis. The best activity was found for 2-hydroxy-4-nitro-N-[4-
(trifluoromethyl)phenyl]benzamide (MIC = 2 μM). 4-Nitrosalicylanilides were also found to 
be active against all Staphylococcus species tested while for MRSA strain 2-hydroxy-4-nitro-
N-[4-(trifluoromethyl)phenyl]benzamide’s MIC was 0.98 μM. None of the nitrosalicylanilides 
was active against Enterococcus sp. J 14365/08 and no considerable activity was found 
against Gram-negative bacteria or fungi. The hepatotoxicity of all nitrosalicylanilides was 
found to be in the range of their MICs for HepG2 cells. 
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1. Introduction 
According to the World Health Organization, tuberculosis (TB) is second only to Human 
Immunodeficiency Virus (HIV) as the greatest killer worldwide due to a single infectious 
agent.
1
 The numbers reported at the Global Tuberculosis Report for 2014 are highlighting the 
severity of the disease. During 2013, 9 million people fell ill with TB and 1.5 million people 
died. Whilst TB is treatable and curable, standard anti-TB drugs, like isoniazid (INH) and 
rifampicin (RMP), have been used for decades, and resistance to the medicines is widespread. 
Clinical strains that are resistant to a single anti-TB drug have been documented in every 
country surveyed giving rise to multidrug-resistant tuberculosis (MDR-TB), extensively drug-
resistant tuberculosis (XDR-TB) and the recently reported totally drug-resistant tuberculosis 
(TDR-TB).
2-4
 In addition, the standard treatment for adult respiratory TB is a regimen of 
drugs developed many years ago and is connected with several adverse effects like 
hepatotoxicity, skin reactions, gastrointestinal and neurological disorders.
5
 Among them 
hepatotoxicity is the most serious one 
6
, directing the current research towards the need to 
enrich the pipeline of available drugs against TB, preferably with candidates offering lower 
cytotoxicity and with new mode of action in comparison to existing drugs. 
On the contrary, various opportunistic human infections are caused by nontuberculous 
mycobacteria (NTM) and, according to the predictions, they will continue to increase their 
incidence at least up to year 2050 mainly due to an increasing elderly population.
7
 The 
treatment of NTM caused infections is complicated and involves multiple medications due to 
the high levels of natural and acquired antibiotic resistance. Furthermore, their current 
treatment share limited efficacy 
8
, and therefore there is a need for new therapeutic strategies 
to be developed. Moreover, severe hospital-acquired infections can be caused due to notable 
drug-resistance complications that have been reported for Gram-positive bacteria, including 
methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae and 
Enterococci.
9
 
Salicylanilides (2-hydroxy-N-phenylbenzamides) have been the subject of several 
medicinal chemistry studies due to their significant in vitro antimicrobial and antifungal 
activities.
10-12
 A number of salicylanilide derivatives have been developed so far with proven 
activity against Mycobacterium tuberculosis (Mtb) and INH-resistant strains.
13-15
 However, 
the precise molecular mode of action of salicylanilides is not clear. It has been previously 
reported that a free phenolic hydroxyl on the salicylic acid moiety is required for activity and 
suggested that they might function as proton shuttles that kill bacterial cells by destroying the 
cellular proton gradient.
16
 On the other hand, salicylanilides and their ester derivatives have 
been reported to act as moderate inhibitors of mycobacterial and human methionine 
aminopeptidases and may target the function of mycobacterial isocitrate lyase which could 
enhance its efficacy due to its particular relevance to mycobacterial latency.
17
 These findings 
have suggested that salicylanilides affect multiple targets to exert their antimicrobial 
properties. Furthermore, salicylanilide esters, carbamates and additional derivatives resulting 
from their conjugation with existing antimicrobial agents, have been suggested to work as 
pro-drugs that are hydrolysed in order to express their activity.
18
 
Although salicylanilides and their derivatives (esters, carbamates etc.) are very potent 
against Mtb, they often share a non-preferable cytotoxic profile.
16, 19
 This drawback has 
limited their utility as potential therapeutics so far. Recent work has focused on the discovery 
of salicylanilide derivatives with decreased cytotoxicity and, under this concept, novel 2-
  
(phenylcarbamoyl)phenyl 4-substituted benzoates were synthesized and found to be active 
against several mycobacteria (0.125-8 μM) while they exhibited no cytotoxicity at 
concentrations of up to 50 μM against a hepatocyte cell line (HepG2).20 The esterification 
products of 5-halogenated salicylanilides with 4-substituted benzoic acids were found to be, 
not only more potent inhibitors of Mtb growth but also to share a preferable cytotoxic profile 
in contrast with the parent salicylanilides. The increased lipophilicity of the afforded 
derivatives limited their solubility in aqueous media and hence their drugability. 
Our ongoing efforts explore the influence of different substitutions on the parent structure 
of salicylanilides, in terms of their activity and cytotoxicity. The introduction of several 
substituents is under investigation. In general, it has been previously reported that an electron 
withdrawing group is favored in the aniline part while the influence of the substituents from 
the acyl moiety is more complex.
21
 The best substituents of the parent salicylanilide structure 
reported so far is –Br or –Cl atoms in position 5 of the salicylic acid part while a –CF3 group 
is favoured in position 4 of the aniline part. More specifically, 5-bromo-2-hydroxy-N-[4-
(trifluoromethyl)phenyl]benzamide and 5-chloro-2-hydroxy-N-[4-
(trifluoromethyl)phenyl]benzamide are inhibiting the growth of Mtb at the concentrations of 1 
and 2 μM respectively. 
Current research in the field of novel antituberculotics on their way to the clinic has 
revealed that many nitro-substituted compounds owe their antimycobacterial activity to the 
presence of a nitro group in their scaffold.
22, 23
 For example, the nitro-reduction of 
nitroimidazole OPC-67683 (also known as delamanid) 
24
 and PA-824 
25
 by F420-deazaflavin-
dependent nitroreductase (Ddn) releases nitric oxide, which is thought to inhibit cytochrome 
oxidase and other targets. In addition, benzothiazinones (BTZ), i.e., BTZ-043 
26
 and BTZ-
derived inhibitors, i.e., CT139 
27
 may interact through their nitro-group with a cysteine 
residue of decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1), either covalently or not, 
thus blocking the first step in the epimerization reaction of decaprenyl-phosphoryl-D-ribose 
(DPR) to decaprenyl-phosphoryl- D-arabinose (DPA) the arabinan donor for arabinogalactan. 
In a similar manner dinitrobenzamides, i.e., DNB1 
28
 are forming a covalent bond with 
Cys387 within the active site of DprE1. More recently, novel dinitrobenzyl-bearing benzazole 
and tetrazole derivatives exhibited high and selective antimycobacterial activity.
29, 30
 
Herein we describe the influence of the introduction of a nitro-group at the salicylic part of 
salicylanilides to their antimycobacterial, antimicrobial and antifungal activities. To the best 
of our knowledge, a structure activity relationship (SAR) concerning the preferable nitro-
substitution of the salicylic part of salicylanilides has not been reported in the literature to 
date, even if some nitro-substituted salicylanilides have been previously presented.
16, 21, 31-34
 
 
2. Results and Discussion 
 
2.1. ADMET properties prediction 
The novel salicylanilides were screened in silico, prior to their synthesis, for their ADMET 
(Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties. The software of 
choice was ADMET Predictor (Simulation Plus, Lancaster, CA), one of the leading computer 
software for advanced predictive modelling of ADMET properties.
35
 The program uses 
molecular description values as inputs to independent mathematical models (generally, 
  
nonlinear machine learning technics) in order to generate estimates for each of the ADMET 
properties.
36
 ADMET Predictor not only rapidly estimates a number of vital ADMET 
properties from molecular structures, but it is able to validate a series of “ADMET Risk” or 
“Tox Risk” parameters. They are parameterized to include thresholds for a wide range of 
calculated and predicted properties that represent potential obstacles to a compound being 
successfully developed as a drug. 
For the majority of the compounds, the analyses indicated no potential risk of either 
ADME/absorption problems related with physico-chemical properties or any stability risk 
related to fast hepatic metabolism. Furthermore, no potential interaction related to inhibition 
of drug biotransformation enzymes was indicated. Most importantly, the tested compounds 
were not found to be potentially related with toxicity or carcinogenicity as indicated by 
parameters of acute toxicity and carcinogenicity in rats expressed as TD50 and LD50 values, 
respectively, mutagenic chromosomal aberrations, or maximum recommended therapeutic 
dose (MRTD). 
More specifically, 17 out of 33 compounds showed a preferable ADMET Risk (score 0-2). 
5 out of 33 compounds presented an acceptable ADMET Risk (score 3), limited by potential 
high lipophilicity and absorption related risk. 11 out of 33 compounds showed a non-
preferable ADMET Risk profile (score 4-5). On the other hand, 28 out of 33 compounds 
showed no potential risk of toxicity (score 0-2) and only 5 out of 33 compounds showed an 
acceptable risk of toxicity (score 3). There was no direct correlation between the position of 
the nitro group and the potential risk of toxicity. Furthermore, the substituent on the aniline 
part is more likely affecting the potential ADMET properties, as halogens in position 3 is 
preferred while trifluoromethyl group and nitro group are not preferable. The ADMET Risk, 
as well as the Tox Risk scores of the screened compounds are summarized in Table S1. With 
the encouraging prediction results the synthesis of the molecules was decided. 
 
2.2. Chemistry 
The synthesis of nitro-containing salicylanilides (1-33) is described in Scheme 1. The final 
compounds were products of the conjugation of nitro-salicylic acids with selected anilines in 
the presence of PCl3 under microwave irradiation. All compounds were isolated with good to 
moderate yields. 
 
Scheme 1: Synthesis of nitro-substituted salicylanilides. 
 
2.3. Antimycobacterial activity 
The nitro-containing salicylanilides (1-33) were evaluated to determine their in vitro 
antimycobacterial activity against Mycobacterium tuberculosis 331/88 (i.e., H37RV), and the 
following nontuberculous mycobacteria: Mycobacterium avium 330/88 and Mycobacterium 
kansasii 235/80 and 6509/96 (a clinical isolated strain). INH, the first-line anti-TB drug, was 
chosen for the comparison performed in this study. Table 1 reports their minimum inhibitory 
concentrations (MICs) as well as their calculated logP values. 
  
 
Table 1. Antimycobacterial activity of nitrosalicylanilides 1-33 
 
  MIC [mol/L 
 R R1 
C 
logP 
Mtb. 331/88 
(H37Rv) 
M. avium 
330/88 
M. kansasii 
235/80 
M. kansasii 
6509/96 
14 d 21 d 14 d 21 d 7 d 14 d 21 d 7 d 14 d 21 d 
1 3-NO2 3-I 3.44 62.5 62.5 500 500 62.5 125 125 125 125 125 
2 3-NO2 3-Br 3.03 62.5 62.5 250 250 62.5 125 125 125 125 125 
3 3-NO2 3-Cl 2.76 62.5 62.5 500 500 62.5 125 250 125 125 125 
4 3-NO2 3-F 2.28 62.5 62.5 500 500 62.5 125 250 125 250 250 
5 3-NO2 3,4-diCl 3.38 16 32 250 250 32 62.5 62.5 62.5 62.5 62.5 
6 3-NO2 3-CF3 3.12 32 32 500 500 32 62.5 62.5 125 250 250 
7 3-NO2 4-CF3 3.12 32 32 250 250 62.5 125 125 62.5 62.5 125 
8 3-NO2 
3-CF3, 4-
NO2 
3.08 16 16 250 500 32 62.5 125 32 62.5 62.5 
9 3-NO2 3-NO2 2.1 62.5 62.5 500 500 62.5 250 250 62.5 250 250 
10 3-NO2 4-NO2 2.1 32 32 125 125 32 62.5 125 62.5 125 125 
11 3-NO2 3,5-diCF3 4.1 8 8 125 125 16 32 32 32 32 32 
12 4-NO2 3-I 3.44 16 16 32 62.5 8 16 16 16 16 16 
13 4-NO2 3-Br 3.03 16 16 32 62.5 8 16 16 16 16 16 
14 4-NO2 3-Cl 2.76 8 16 32 62.5 8 16 16 16 16 16 
15 4-NO2 3-F 2.28 16 16 62.5 125 16 16 32 16 32 32 
16 4-NO2 3,4-diCl 3.38 4 8 32 62.5 4 8 8 8 16 16 
17 4-NO2 3-CF3 3.12 8 8 62.5 62.5 8 16 16 8 16 16 
18 4-NO2 4-CF3 3.12 2 4 32 32 2 4 8 4 8 8 
19 4-NO2 
3-CF3, 4-
NO2 
3.08 16 16 62.5 62.5 16 32 32 16 32 32 
20 4-NO2 3-NO2 2.1 32 32 125 125 32 32 62.5 32 32 32 
21 4-NO2 4-NO2 2.1 8 16 62.5 62.5 8 16 32 32 32 32 
22 4-NO2 3,5-diCF3 4.1 4 8 32 32 8 16 16 16 16 16 
23 5-NO2 3-I 3.44 16 16 125 125 16 32 62.5 32 62.5 62.5 
24 5-NO2 3-Br 3.03 16 16 125 250 32 62.5 62.5 32 62.5 62.5 
25 5-NO2 3-Cl 2.76 16 16 125 125 16 32 62.5 32 62.5 62.5 
26 5-NO2 3-F 2.28 16 32 125 125 16 62.5 62.5 32 62.5 62.5 
27 5-NO2 3,4-diCl 3.38 8 16 125 125 16 32 32 32 32 32 
28 5-NO2 3-CF3 3.12 8 16 125 125 16 32 62.5 32 62.5 62.5 
29 5-NO2 4-CF3 3.12 8 8 62.5 62.5 8 16 32 16 32 32 
30 5-NO2 
3-CF3, 4-
NO2 
3.08 32 32 125 125 32 62.5 125 62.5 62.5 125 
31 5-NO2 3-NO2 2.1 62.5 62.5 125 125 16 62.5 125 62.5 125 125 
32 5-NO2 4-NO2 2.1 62.5 125 250 250 16 62.5 125 62.5 125 125 
33 5-NO2 3,5-diCF3 4.1 16 16 32 32 16 32 32 16 32 32 
  
INH = isoniazid 
 
According to the nitro-substitution of the salicylic part, the tested compounds could be 
divided into three groups: Group 1 includes 3-NO2 derivatives (1-11); Group 2 includes 4-
NO2 derivatives (12-22); and Group 3 includes 5-NO2 derivatives (23-33). It was observed 
that the most preferable position of nitro-group is position 4 of the salicylic part, followed by 
the nitro-substitution in position 5. Nitro-substitution in position 3 of the salicylic part was the 
least preferable. 
Some nitrosalicylanilides exhibited good to moderate activity against Mtb. For the 4-nitro 
substituted salicylanilides, the activity ranged between 2-32 μM. The best activity was found 
for 2-hydroxy-4-nitro-N-[4-(trifluoromethyl)phenyl]benzamide (18) (MIC = 2 μM). The 
favorable substitutions in the aniline part, regardless of the position of the nitro-group at the 
salicylic part, were the mono- or bis-trifluoromethyl- substitution. This is probably due to the 
increased lipophilicity (higher calculated logP value) of the molecule when bearing the 
trifluoromethyl moiety and is in accordance with previous results regarding the preferable 
substitution in the aniline part.
21
 Furthermore, it is noteworthy that the presence of a nitro 
group in the aniline part of the molecule resulted less active molecules as a result of their 
decreased lipophilicity (lower calculated logP values). 
Nitro-substituted salicylanilides did not show any considerable active against M. avium 
330/88 (MIC ≥ 32 μM). On the other hand, all tested molecules were more active than INH 
against M. kansasii 235/80, while 2-hydroxy-4-nitro-N-[4-(trifluoromethyl)phenyl]benzamide 
(18) was the most active (MIC = 8 μM after 21 days). The same derivative (18) was similarly 
active with INH against M. kansasii 6509/96 (MIC = 8 μM after 21 days). 
 
2.4. Antibacterial and antifungal activity 
Our efforts to further investigate the biological activity of the nitrosalicylanilides, the 
derivatives that bear the nitro-group in positions 4 and 5 of the salicylic part involved testing 
against eight bacterial and eight fungal strains. More specifically, the selected molecules were 
tested against Staphylococcus aureus CCM 4516/08, methicillin-resistant Staphylococcus 
aureus H 5996/08 (MRSA), Staphylococcus epidermis H 6966/08, Enterococcus sp. J 
14365/08, Escherichia coli CCM 4517, Klebsiella pneumoniae D 11750/08, extended 
spectrum β-lactamases producing Klebsiella pneumoniae J 14368/08, and Pseudomonas 
aeruginosa CCM 1961. Furthermore, the selected nitrosalicylanilides were tested against four 
Candida strains (Candida albicans ATCC 44859, Candida tropicalis 156, Candida krusei 
E28, and Candida glabrata 20/I), Trichosporon asahii 1188 and three filamentous fungi 
(Aspergillus fumigatus 231, Absidia corymbifera 272, and Trichophyton mentagrophytes 
445). Benzylpenicillin (PNC) and fluconazole (FLU) were used for comparison during 
antibacterial and antifungal activity studies respectively. 
Similar to their antimycobacterial activity, 4-nitro substituted salicylanilides were found to 
be more active against all different Staphylococcus species than their 5-nitro substituted 
analogues (Table 2). The range of MIC values were between 1-62.5 μM and 3.9-500 μM, 
respectively. The 3,5-bis(trifluoromethyl) moiety was the best substitution for the aniline part 
for all the different Staphylococcus species tested. The most active compound against all 
different Staphylococcus species was N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-4-
nitrobenzamide (22), which exhibited MIC of 1.95 μM for S. aureus CCM 4516/08 and S. 
epidermis, while for MRSA strain the compound’s MIC was 0.98 μM. Once again, the 
presence of a nitro-group in the aniline part of the molecule was found to drastically decrease 
INH - 0.5 1 250 250 250 250 250 4 8 8 
  
the activity. On the other hand, no considerable activity was found against Enterococcus sp. J 
14365/08 (MIC ≥ 62.5 μM). In comparison with PNC, none of the nitrosalicylanilides was 
more active against Staphylococcus aureus CCM 4516/08 while 4-nitrosalicylanilides were 
always more active against MRSA and Staphylococcus epidermis H 6966/08. 
 
Table 2. Antibacterial activity of nitrosalicylanilides 12-33 (Gram-positive bacteria) 
 
 
R1 R2 
MIC/IC95 (μmol/L) 
 SA MRSA SE EF 
 24h 48h 24h 48h 24h 48h 24h 48h 
12 4-NO2 3-I 3.9 3.9 3.9 3.9 15.62 15.62 >500 >500 
13 4-NO2 3-Br 3.9 3.9 3.9 3.9 3.9 3.9 500 500 
14 4-NO2 3-Cl 7.81 15.62 7.81 15.62 7.81 15.62 500 >500 
15 4-NO2 3-F 15.62 31.25 15.62 31.25 15.62 31.25 500 >500 
16 4-NO2 3,4-diCl 3.9 3.9 1.95 1.95 1.95 1.95 125 500 
17 4-NO2 3-CF3 3.9 3.9 1.95 1.95 1.95 7.81 250 500 
18 4-NO2 4-CF3 7.81 7.81 1.95 1.95 1.95 7.81 250 250 
19 4-NO2 
3-CF3, 
4-NO2 
7.81 7.81 3.9 3.9 7.81 7.81 250 500 
20 4-NO2 3-NO2 62.5 62.5 125 125 31.25 62.5 >250 >250 
21 4-NO2 4-NO2 62.5 62.5 31.25 31.25 62.5 62.5 500 >500 
22 4-NO2 
3,5-
diCF3 
1.95 1.95 0.98 0.98 1.95 1.95 62.5 125 
23 5-NO2 3-I 31.25 31.25 31.25 31.25 31.25 31.25 250 >500 
24 5-NO2 3-Br 31.25 62.5 31.25 62.5 31.25 250 500 >500 
25 5-NO2 3-Cl 31.25 62.5 62.5 62.5 62.5 62.5 500 >500 
26 5-NO2 3-F 125 125 125 125 125 250 >500 >500 
27 5-NO2 3,4-diCl 31.25 31.25 31.25 31.25 62.5 62.5 125 125 
28 5-NO2 3-CF3 31.25 31.25 31.25 31.25 31.25 31.25 >500 >500 
29 5-NO2 4-CF3 31.25 31.25 31.25 31.25 15.62 15.62 >500 >500 
30 5-NO2 
3-CF3, 
4-NO2 
62.5 62.5 31.25 31.25 125 125 >500 >500 
31 5-NO2 3-NO2 500 500 500 500 500 500 >500 >500 
32 5-NO2 4-NO2 250 250 250 250 500 500 >500 >500 
33 5-NO2 
3,5-
diCF3 
3.9 3.9 7.81 7.81 15.62 15.62 500 500 
PNC   0.98 0.98 62.5 125 250 250 7.81 15.62 
SA: Staphylococcus aureus CCM 4516/08, MRSA: Methicillin-resistant Staphylococcus 
aureus H 5996/08, SE: Staphylococcus epidermidis H 6966/08, EF: Enterococcus sp. J 
14365/08. PNC: benzylpenicillin. 
 
None of the tested compounds was found to be active against any of the tested Gram-
negative bacteria (Table S2). In addition, nitrosalicylanilides were not found to possess any 
considerable antifungal activity (Table S3). 
 
2.5. Cytotoxicity evaluation 
12 of the synthesized nitrosalicylanilides were evaluated for their cytotoxic properties 
using an MTT assay in the HepG2 cell model. HepG2 cells represent the most likely target 
  
tissue of antituberculotics-related toxicity, which often complicates the treatment of TB.
37
 The 
tested compounds were chosen according to their antimycobacterial activity and the position 
of the nitro-group in the salicylic part. More specifically, 4 compounds from each different 
nitro-substitution of the salicylic part were selected for cytotoxicity experiments. The 
substitution for the aniline part was: 3,4-diCl, 3-CF3, 4-CF3 and 3,5-diCF3. The cytotoxicity 
results as well as the selectivity indexes (SI) for the tested compounds are summarized in 
Table 3. 
 
Table 3. Cytotoxicity of selected nitrosalicylanilides  
 
 R1 R
2 IC50 (μM) for HepG2 
cells 
Selectivity index (SI) 
for Mtb 
5 3-NO2 3,4-diCl 5.9 0.184-0.369 
6 3-NO2 3-CF3 8.9 0.278 
7 3-NO2 4-CF3 8.0 0.250 
11 3-NO2 3,5-diCF3 7.4 0.925 
16 4-NO2 3,4-diCl 1.4 0.175-0.350 
17 4-NO2 3-CF3 2.8 0.350 
18 4-NO2 4-CF3 1.2 0.300-0.600 
22 4-NO2 3,5-diCF3 4.4 0.550-1.100 
27 5-NO2 3,4-diCl 8.9 0.556-1.113 
28 5-NO2 3-CF3 7.4 0.463-0.925 
29 5-NO2 4-CF3 3.5 0.438 
33 5-NO2 3,5-diCF3 13.9 0.869 
SI = IC50/MIC100 
 
The IC50 values for the tested compounds were in the range of 1.2 to 13.9 μM. According 
to the position of the nitro group, 4-nitro substituted salicylanilides showed consistently the 
lowest IC50 values (1.2-4.4 μM), while the 3- and 5-nitro- substituted analogues showed 
higher IC50 values (3.5-13.9 μM). The highest rate of cytotoxicity was found for 2-hydroxy-4-
nitro-N-[4-(trifluoromethyl)phenyl]benzamide (18). On the other hand, the highest IC50 was 
found for N-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxy-5-nitrobenzamide (33). There is no 
direct correlation between the substitution at the aniline part and cytotoxicity. SI values for 
the tested compounds was always ≤ 1.113 indicating that antimycobacterial activity trends 
with cytotoxicity. 
 
3. Conclusions 
In order to investigate the influence of the introduction of a nitro group at the salicylic part 
of salicylanilides on their antimycobacterial, antimicrobial and antifungal activities, a series of 
novel salicylanilides, containing nitro group in their salicylic part, were designed and 
synthesized. All compounds were screened in silico with ADMET Predictor prior to their 
synthesis, in order to obtain an estimated prediction about their potential ADME properties 
and toxicity risk. The prediction revealed no potential risk of either ADME/absorption 
problems related with physico-chemical properties or any stability risk related to fast hepatic 
metabolism for the majority of the screened compounds. In addition the nitrosalicylanilides 
showed minimum to acceptable risk of toxicity as indicated from their Tox Risk score. 
  
The synthesized compounds were evaluated for their antimycobacterial activity against 
Mtb and found to possess activity in the low micromolar range, comparable with the 5-
halogenated salicylanilides which are the most active salicylanilides presented to date. The 
most preferable position of nitro-group was found to be position 4 of the salicylic part, 
followed by the nitro substitution in position 5. Nitro substitution in position 3 of the salicylic 
part was the least preferable. Although nitro-substituted salicylanilides did not show any 
considerable activity against M. avium, they were more active than INH against M. kansasii 
235/80. 2-hydroxy-4-nitro-N-[4-(trifluoromethyl)phenyl]benzamide (18) was found to possess 
similar activity with INH against M. kansasii 6509/96. Furthermore, 4-nitro substituted 
salicylanilides were found to be more active against all Staphylococcus species tested than 
their 5-nitro substituted analogues while none of the nitrosalicylanilides presented 
considerable activity against Enterococcus sp. J 14365/08. In addition, the synthesized 
compounds were found to be inactive against all tested Gram-negative bacteria and fungi. 
Nitro substituted salicylanilides were found to share a non-preferable cytotoxic profile as their 
IC50 values against HepG2 cells were found to be in the range of their MIC values. 
The presence of a free phenolic hydroxyl at the salicylanilide scaffold has been suggested 
to be responsible for the cytotoxicity of these molecules.
16
 Several derivatives of 
salicylanilides have been proved to retain their activity while possessing a less cytotoxic 
profile.
20, 38
 Under this concept, 4-nitrosalicylanilides could be potential candidates for further 
development by preparing their 4-(substituted)benzoates. This method was previously 
reported by our group for 5-halogenated salicylanilides affording the more active 
salicylanilide (4-substituted)benzoates with a preferable cytotoxic profile than the parent 
salicylanilides.
20
 The only limitation observed for the (4-substituted)benzoates of 5-
halogenated salicylanilides was their poor solubility in aqueous media. It is expected that the 
presence of a nitro group at the salicylic part, instead of a halogen, will have a positive impact 
at the solubility of 4-(substituted)benzoates of 4-nitrosalicylanilides. The suggestion 
concerning the solubility is in agreement with the comparison of the predicted calculated logP 
values between 4-(substituted)benzoates of 4-nitrosalicylanilides and 4-(substituted)benzoates 
of 5-halogenated salicylanilides (Table S4). 
  
4. Experimental part 
 
4.1. Chemistry 
 
4.1.1. General methods 
All of the reagents and solvents were purchased from Sigma-Aldrich (Darmstadt, 
Germany) or Penta Chemicals (Prague, Czech Republic) and used as received. The reactions 
and the purity of the products were monitored by thin-layer chromatography using a mixture 
of hexane to ethyl acetate of 4:1 or 2:1 as eluent. The plates were coated with 0.2-mm Merck 
60 F254 silica gel and were visualized by UV irradiation (254 nm). The melting points were 
determined on a Büchi Melting Point B-540 apparatus using open capillaries, and the reported 
values are uncorrected. 
Elemental analysis (C, H and N) was performed on an automatic microanalyser CHNS-O 
CE instrument (FISONS EA 1110, Milano, Italy). Infrared spectra (ATR) were recorded on a 
FT-IR spectrometer (Nicolet 6700 FT-IR) in the range of 400-4000 cm
-1
. The NMR spectra 
were measured in DMSO at ambient temperature using a Varian V NMR S500 instrument 
(500 MHz for 
1
H and 125 MHz for 
13
C, Varian Comp., Palo Alto, CA, USA) or a Varian 
  
Mercury-Vxbb 300 (300 MHz for 
1
H and 75.5 MHz for 
13
C, Varian, Inc., Palo Alto, CA, 
USA). The chemical shifts, δ, are given in ppm with respect to tetramethylsilane, which was 
used as an internal standard. The coupling constants (J) are reported in Hz. 
The calculated logP values (ClogP), which are the logarithms of the partition coefficients 
for octan-1-ol/water, were determined using the CS ChemOffice Ultra program (version 12.0, 
Cambridge-Soft, Cambridge, MA, USA). 
 
4.1.2. Synthesis 
All salicylanilides (1-33) were synthesized via a previously described method 
39
 with 
yields of 60-85%. This microwave assisted syntheses were performed in a microwave reactor 
(530 W, 600 rpm, MicroSYNTH Milestone) for 30-60 min to reflux. All compounds were 
purified by recrystallization from ethanol or acetone or mixture of ethanol/acetone. 
 
4.1.2.1. 2-Hydroxy-N-(3-iodophenyl)-3-nitrobenzamide (1). Yellow solid; yield 74%; 
mp 188.5-189.5 
o
C. IR (ATR): 3376, 3083, 1676 (CO). 
1H NMR (500 MHz, DMSO): δ 10.73 
(1H, s, NH), 8.17 (1H, s, H2’), 8.16 (1H, dd, J = 8.0 Hz, J = 1.0 Hz, H4), 8.13 (1H, dd, J = 8.0 
Hz, J = 1.0 Hz, H6), 7.70 (1H, d, J = 8.5 Hz, H4’), 7.53 (1H, d, J = 7.5 Hz, H6’), 7.20 (1H, t, 
J = 8.0 Hz, H5’), 7.15 (1H, t, J = 8.0 Hz, H5). 13C NMR (125 MHz, DMSO): δ 166.35, 
152.94, 138.38, 138.23, 134.08, 133.30, 130.97, 129.37, 128.75, 122.11, 120.43, 118.73, 
94.59. Anal. Calcd for C13H9IN2O4 (384.13): C, 40.65; H, 2.36; N, 7.29. Found: C, 40.60; H, 
2.38; N, 7.28. 
4.1.2.2. 2-Hydroxy-N-(3-bromophenyl)-3-nitrobenzamide (2). Yellow solid; yield 80%; 
mp 160 
o
C. IR (ATR): 3375, 3084, 1677 (CO). 
1H NMR (300 MHz, DMSO): δ 10.79 (1H, s, 
NH), 8.16 (1H, dd, J = 8.1 Hz, J = 1.5 Hz, H4), 8.13 (1H, dd, J = 7.2 Hz, J = 1.8 Hz, H6), 
8.03 (1H, s, H2’), 7.67-7.65 (1H, m, H5’), 7.37-7.35 (2H, m, H4’, H6’), 7.15 (1H, t, J = 8.1 
Hz, H5). 
13
C NMR (75 MHz, DMSO): δ 166.20, 152.64, 139.45, 138.03, 133.99, 130.80, 
128.57, 127.20, 123.32, 122.20, 121.46, 119.76, 118.64. Anal. Calcd for C13H9BrN2O4 
(337.13): C, 46.32; H, 2.69; N, 8.31. Found: C, 45.83; H, 2.90; N, 8.02. 
4.1.2.3. 2-Hydroxy-N-(3-chlorophenyl)-3-nitrobenzamide (3). Yellow solid; yield 85%; 
mp 153-154 
o
C. IR (ATR): 3365, 3091, 1667 (CO). 
1H NMR (300 MHz, DMSO): δ 10.81 
(1H, s, NH), 8.16 (1H, dd, J = 7.8 Hz, J = 1.2 Hz, H4), 8.13 (1H, dd, J = 8.4 Hz, J = 1.5 Hz, 
H6), 7.89 (1H, t, J = 1.8 Hz, H2’), 7.62 (1H, dd, J = 8.1 Hz, J = 0.9 Hz, H6’), 7.15 (1H, t, J = 
7.8 Hz, H5’), 7.25 (1H, dd, J = 7.8 Hz, J = 1.5 Hz, H4’), 7.15 (1H, t, J = 8.1 Hz, H5). 13C 
NMR (75 MHz, DMSO): δ 166.21, 152.63, 139.33, 138.02, 134.00, 133.06, 130.51, 128.56, 
124.31, 122.27, 120.47, 119.37, 118.65. Anal. Calcd for C13H9ClN2O4 (292.68): C, 53.35; H, 
3.10; N, 9.57. Found: C, 52.80; H, 3.51; N, 9.32. 
4.1.2.4. 2-Hydroxy-N-(3-fluorophenyl)-3-nitrobenzamide (4). Yellow solid; yield 76%; 
mp 111-112 
o
C. IR (ATR): 3366, 3088, 1662 (CO). 
1H NMR (500 MHz, DMSO): δ 10.81 
(1H, s, NH), 8.16 (1H, dd, J = 7.8 Hz, J = 1.4 Hz, H4), 8.13 (1H, dd, J = 8.3 Hz, J = 1.5 Hz, 
H6), 7.67 (1H, dt, J = 11.5 Hz, J = 2.1 Hz, H2’), 7.48 (1H, d, J = 8.3 Hz, H6’), 7.43 (1H, dt, J 
= 10.0 Hz, J = 7.4 Hz, H5’) 7.15 (1H, t, J = 7.9 Hz, H5), 7.00 (1H, td, J = 8.5 Hz, J = 2.2 Hz, 
H4’). 13C NMR (125 MHz, DMSO): δ 166.17, 162.00 (d, J = 242.2 Hz), 152.60, 139.57 (d, J 
= 11.1 Hz), 137.98, 134.00, 130.43 (d, J = 9.4 Hz), 128.51, 122.30, 118.64, 111.08 (d, J = 
21.0 Hz), 107.77 (d, J = 26.3 Hz). Anal. Calcd for C13H9FN2O4 (276.22): C, 56.53; H, 3.28; 
N, 10.14. Found: C, 55.94; H, 3.67; N, 9.92. 
4.1.2.5. 2-Hydroxy-N-(3,4-dichlorophenyl)-3-nitrobenzamide (5). Yellow solid; yield 
73%; mp 153-154 
o
C. IR (ATR) 3365, 3107, 1673 (CO). 
1H NMR (300 MHz, DMSO): δ 
  
10.88 (1H, s, NH), 8.13 (2H, d, J = 8.1 Hz, H4, H6), 8.07 (1H, s, H2’), 7.65 (2H, s, H5’, H6’), 
7.15 (1H, t, J = 8.1 Hz, H5). 
13C NMR (75 MHz, DMSO): δ 166.10, 152.42, 138.09, 138.01, 
134.08, 131.03, 130.74, 128.56, 126.09, 122.55, 122.07, 120.83, 118.72. Anal. Calcd for 
C13H8Cl2N2O4 (327.12): C, 47.73; H, 2.47; N, 8.56. Found: C, 47.02; H, 2.78; N, 8.09. 
4.1.2.6. 2-Hydroxy-N-[3-(trifluoromethyl)phenyl]-3-nitrobenzamide (6). Yellow solid; 
yield 76%; mp 142-143.5 
o
C. IR (ATR): 3364, 3089, 1665 (CO). 
1
H NMR (500 MHz, 
DMSO): δ 10.94 (1H, s, NH), 8.17 (1H, dd, J = 7.8 Hz, J = 1.4 Hz, H4), 8.16 (1H, d, J = 1.5 
Hz, H2’), 8.14 (1H, dd, J = 8.3 Hz, J = 1.5 Hz, H6), 7.95 (1H, d, J = 8.3 Hz, H4’), 7.64 (1H, t, 
J = 8.0 Hz, H5’), 7.52 (1H, d, J = 7.8 Hz, H6’), 7.16 (1H, t, J = 7.8 Hz, H5). 13C NMR (125 
MHz, DMSO): δ 160.30, 152.54, 138.72, 138.05, 134.02, 130.07, 129.48 (q, J = 31.8 Hz), 
128.55, 124.51, 124.03 (q, J = 270.00 Hz), 122.35, 120.87 (q, J = 3.8 Hz), 118.66, 117.06 (q, 
J = 4.00 Hz). Anal. Calcd for C14H9F3N2O4 (326.23): C, 51.54; H, 2.78; N, 8.59. Found: C, 
51.03; H, 2.94; N, 8.22. 
4.1.2.7. 2-Hydroxy-N-[4-(trifluoromethyl)phenyl]-3-nitrobenzamide (7). Yellow solid; 
yield 69%; mp 156-157 
o
C. IR (ATR): 3362, 3093, 1678 (CO). 
1
H NMR (500 MHz, DMSO): 
δ 10.96 (1H, s, NH), 8.16 (1H, dd, J = 7.8 Hz, J = 1.4 Hz, H4), 8.14 (1H, dd, J = 8.3 Hz, J = 
1.5 Hz, H6), 7.94 (2H, d, J = 8.5 Hz, H3’,H5’), 7.76 (2H, d, J = 8.5 Hz, H2’,H4’), 7.16 (1H, t, 
J = 8.0 Hz, H5). 
13C NMR (125 MHz, DMSO): δ 166.22, 152.41, 141.63, 137.95, 134.21, 
128.47, 126.05 (q, J = 3.8 Hz), 124.42 (q, J = 32.5 Hz), 124.27 (q, J = 270.0 Hz), 122.87, 
120.74, 118.70. Anal. Calcd for C14H9F3N2O4 (326.23): C, 51.54; H, 2.78; N, 8.59. Found: C, 
51.10; H, 2.98; N, 8.37. 
4.1.2.8. 2-Hydroxy-3-nitro-N-(4-nitro-3-[trifluoromethyl)phenyl]benzamide (8). 
Yellow solid; yield 78%; mp 161-162 
o
C. IR (ATR): 3331, 3096, 1686 (CO). 
1
H NMR (500 
MHz, DMSO): δ 11.38 (1H, s, NH), 8.39 (1H, d, J = 2.0 Hz, H2’), 8.26 (1H, d, J = 8.9 Hz, 
H5’), 8.21 (1H, dd, J = 9.0 Hz, J = 2.1 Hz, H6’), 8.14 (1H, dd, J = 8.2 Hz, J = 1.7 Hz, H4), 
8.08 (1H, dd, J = 7.7 Hz, J = 1.6 Hz, H6), 7.16 (1H, t, J = 7.9 Hz, H5). 
13
C NMR (125 MHz, 
DMSO): δ 166.12, 151.80, 142.97, 142.05, 138.00, 134.51, 128.49, 127.63, 123.90, 123.67, 
122.84 (q, J = 33.3 Hz), 122.02 (q, J = 271 Hz), 118.85, 118.54 (q, J = 6.0 Hz). Anal. Calcd 
for C14H8F3N3O6 (371.23): C, 45.30; H, 2.17; N, 11.32. Found: C, 44.65; H, 2.61; N, 10.87. 
4.1.2.9. 2-Hydroxy-3-nitro-N-(3-nitrophenyl)benzamide (9). Yellow solid; yield 66%; 
mp 204-205 
o
C. IR (ATR): 3350, 3112, 1670 (CO). 
1H NMR (500 MHz, DMSO): δ 11.06 
(1H, s, NH), 8.71 (1H, t, J = 2.1 Hz, H2’), 8.16 (1H, dd, J = 5.7 Hz, J = 1.6 Hz, H6’), 8.14 
(1H, dd, J = 6.2 Hz, J = 1.7 Hz, H4’), 8.08 (1H, dd, J = 8.2 Hz, J = 1.3 Hz, H4), 8.01 (1H, dd, 
J = 8.1 Hz, J = 2.3 Hz, H6), 7.68 (1H, t, J = 8.2 Hz, H5’), 7.16 (1H, t, J = 8.1 Hz, H5). 13C 
NMR (125 MHz, DMSO): δ 166.32, 152.39, 147.90, 139.17, 138.02, 134.14, 130.26, 128.59, 
126.72, 122.62, 118.97, 118.77, 114.93. Anal. Calcd for C13H9N3O6 (303.23): C, 51.49; H, 
2.99; N, 13.96. Found: C, 50.68; H, 3.24; N, 13.47. 
4.1.2.10. 2-Hydroxy-3-nitro-N-(4-nitrophenyl)benzamide (10). Yellow solid; yield 60%; 
mp 221-222 
o
C. IR (ATR): 3355, 3100, 1677 (CO). 
1H NMR (300 MHz, DMSO): δ 11.74 
(1H, s, NH), 8.27 (2H, d, J = 9.1 Hz, H3’,H5’), 8.09 (2H, d, J = 7.8 Hz, H4,H6), 7.97 (2H, d, 
J = 9.1 Hz, H2’,H6’), 7.03 (1H, t, J = 7.9 Hz, H5). 13C NMR (75 MHz, DMSO): δ 165.99, 
153.86, 144.69, 142.73, 138.30, 134.68, 128.59, 124.93, 123.83, 120.09, 117.29. Anal. Calcd 
for C13H9N3O6 (303.23): C, 51.49; H, 2.99; N, 13.96. Found: C, 50.72; H, 3.37; N, 13.40. 
4.1.2.11. N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-3-nitrobenzamide (11). Yellow 
solid; yield 71%; mp 183-184 
o
C. IR (ATR): 3355, 3109, 1671 (CO). 
1
H NMR (300 MHz, 
DMSO): δ 11.21 (1H, s, NH), 8.41 (2H, s, H2’,H6’), 8.14 (1H, dd, J = 8.0 Hz, J = 1.5 Hz, 
H4), 8.12 (1H, dd, J = 8.0 Hz, J = 1.5 Hz, H6), 7.17 (1H, t, J = 8.1 Hz, H5). 
13
C NMR (75 
MHz, DMSO): δ 166.28, 152.09, 140.09, 138.10, 134.20, 130.79 (q, J = 33.0 Hz), 128.60, 
  
123.17 (q, J = 271.0 Hz), 122.95, 120.40, 118.81, 117.18 (q, J = 3.7 Hz). Anal. Calcd for 
C15H8F6N2O4 (394.23): C, 45.70; H, 2.05; N, 7.11. Found: C, 45.08; H, 2.31; N, 6.89. 
4.1.2.12. 2-Hydroxy-N-(3-iodophenyl)-4-nitrobenzamide (12). Yellow solid; yield 77%; 
mp 243-245 
o
C. IR (ATR): 3337, 3125, 1640 (CO). 
1H NMR (500 MHz, DMSO): δ 11.75 
(1H, bs, OH), 10.49 (1H, s, NH), 8.23 (1H, s, H2’), 7.92 (1H, d, J = 9.2 Hz, H6), 7.78-7.74 
(2H, m, H3,H5), 7.68 (1H, d, J = 8.1 Hz, H4’), 7.50 (1H, d, J = 9.2 Hz, H6’), 7.17 (1H, t, J = 
8.0 Hz, H5’). 13C NMR (125 MHz, DMSO): δ 164.01, 156.57, 149.49, 139.74, 132.66, 
130.83, 130.81, 128.30, 127.10, 119.44, 113.66, 111.16, 94.55. Anal. Calcd for C13H9IN2O4 
(384.13): C, 40.65; H, 2.36; N, 7.29. Found: C, 40.48; H, 2.59; N, 7.01. 
4.1.2.13. N-(3-Bromophenyl)-2-hydroxy-4-nitrobenzamide (13). Yellow solid; yield 
68%; mp 220-221.5 
o
C. IR (ATR): 3313, 3085, 1639 (CO). 
1H NMR (500 MHz, DMSO): δ 
11.79 (1H, bs, OH), 10.49 (1H, s, NH), 8.08 (1H, s, H2’), 7.92 (1H, d, J = 9.2 Hz, H6), 7.78-
7.74 (2H, m, H3,H5), 7.67-7.65 (1H, m, H6’), 7.35-7.30 (2H, m, H4’,H5’). 13C NMR (125 
MHz, DMSO): δ 164.06, 156.56, 149.50, 139.93, 130.84, 130.77, 127.07, 126.72, 122.46, 
121.54, 118.98, 113.65, 111.17. Anal. Calcd for C13H9BrN2O4 (337.13): C, 46.32; H, 2.69; N, 
8.31. Found: C, 45.91; H, 3.01; N, 7.96. 
4.1.2.14. N-(3-Chlorophenyl)-2-hydroxy-4-nitrobenzamide (14). Yellow solid; yield 
71%; mp 227-228 
o
C. IR (ATR): 3329, 3080, 1637 (CO). 
1H NMR (500 MHz, DMSO): δ 
11.80 (1H, bs, OH), 10.57 (1H, s, NH), 7.95-7.91 (2H, m, H6,H2’), 7.78-7.74 (2H, m, 
H3,H5), 7.61 (1H, dd, J = 8.2 Hz, J = 1.0 Hz, H4’), 7.39 (1H, t, J = 8.1 Hz, H5’), 7.19 (1H, 
dd, J = 7.8 Hz, J = 1.8 Hz, H6’). 13C NMR (125 MHz, DMSO): δ 164.06, 156.56, 149.50, 
139.80, 133.11, 130.85, 130.47, 127.06, 123.82, 119.62, 118.59, 113.65, 111.17. Anal. Calcd 
for C13H9ClN2O4 (292.68): C, 53.35; H, 3.10; N, 9.57. Found: C, 52.98; H, 3.41; N, 9.30. 
4.1.2.15. N-(3-Fluorophenyl)-2-hydroxy-4-nitrobenzamide (15). Yellow solid; yield 
75%; mp 238-239 
o
C. IR (ATR): 3393, 3110, 1684 (CO). 
1H NMR (500 MHz, DMSO): δ 
11.80 (1H, bs, OH), 10.59 (1H, s, NH), 7,93 (1H, d, J = 8.2 Hz, H6), 7.78-7.74 (2H, m, 
H3,H5), 7.72 (1H, d, J = 11.6 Hz, H2’), 7.47 (1H, d, J = 8.3 Hz, H6’), 7.43-7.37 (1H, m, 
H5’), 7.19 (1H, td, J = 8.4 Hz, J = 2.3 Hz, H4’). 13C NMR (125 MHz, DMSO): δ 164.02, 
162.26 (d, J = 241.6 Hz), 156.52, 149.49, 140.07 (d, J = 11.0 Hz), 130.87, 130.44 (d, J = 9.5 
Hz), 127.13, 115.91, 113.66, 111.16, 110.58 (d, J = 21.1 Hz), 106.93 (d, J = 26.3 Hz). Anal. 
Calcd for C13H9FN2O4 (276.22): C, 56.53; H, 3.28; N, 10.14. Found: C, 55.87; H, 3.65; N, 
9.98. 
4.1.2.16. N-(3,4-Dichlorophenyl)-2-hydroxy-4-nitrobenzamide (16). Yellow solid; yield 
83%; mp 230-232 
o
C. IR (ATR): 3325, 3115, 1638 (CO). 
1H NMR (500 MHz, DMSO): δ 
11.79 (1H, bs, OH), 10.67 (1H, s, NH), 8.12 (1H, d, J = 2.0 Hz, H2’), 7.91 (1H, d, J = 8.2 Hz, 
H6), 7.78-7.74 (2H, m, H3,H5), 7.66 (1H, dd, J = 8.8 Hz, J = 2.2 Hz, H6’), 7.61 (1H, d, J = 
8.8 Hz, H5’). 13C NMR (125 MHz, DMSO): δ 164.13, 156.53, 149.54, 138.51, 131.06, 
130.90, 130.73, 127.10, 125.57, 121.31, 120.18, 113.64, 111.18. Anal. Calcd for 
C13H8Cl2N2O4 (327.12): C, 47.73; H, 2.47; N, 8.56. Found: C, 47.24; H, 2.71; N, 8.29. 
4.1.2.17. 2-Hydroxy-4-nitro-N-[3-(trifluoromethyl)phenyl]benzamide (17). Yellow 
solid; yield 65%; mp 215-216 
o
C. IR (ATR): 3316, 3085, 1639 (CO). 
1
H NMR (500 MHz, 
DMSO): δ 11.80 (1H, bs, OH), 10.73 (1H, s, NH), 8.23 (1H, s, H2’), 7.96-7.91 (2H, m, 
H6,H4’), 7.78-7.74 (2H, m, H3,H5), 7.61 (1H, t, J = 8.0 Hz, H5’), 7.48 (1H, d, J = 7.7 Hz, 
H6’). 13C NMR (125 MHz, DMSO): δ 164.50, 156.84, 149.73, 139.35, 131.03, 130.21, 
129.71 (q, J = 31.6 Hz), 127.23, 124.26 (q, J = 271.3 Hz), 123.96, 120.61 (q, J = 3.7 Hz), 
116.44 (q, J = 4.1 Hz), 113.80, 111.39. Anal. Calcd for C13H9F3N2O4 (326.23): C, 51.54; H, 
2.78; N, 8.59. Found: C, 51.11; H, 2.96; N, 8.20. 
  
4.1.2.18. 2-Hydroxy-4-nitro-N-[4-(trifluoromethyl)phenyl]benzamide (18).
31
 Yellow 
solid; yield 69%; mp 215-216 
o
C. IR (ATR): 3401, 3109, 1665 (CO). 
1
H NMR (500 MHz, 
DMSO): δ 11.80 (1H, bs, OH), 10.74 (1H, s, NH), 8.23 (1H, s, H2’), 7.97-7.91 (3H, m, 
H6,H2’, H6’), 7.78-7.75 (2H, m, H3,H5), 7.73 (2H, d, J = 8.7 Hz, H3’,H5’). 13C NMR (125 
MHz, DMSO): δ 164.25, 156.49, 149.53, 141.99, 130.94, 127.29, 126.09 (q, J = 3.7 Hz), 
124.31 (q, J = 270.0 Hz), 124.05 (q, J = 32.1 Hz), 120.03, 113.67, 111.16. Anal. Calcd for 
C13H9F3N2O4 (326.23): C, 51.54; H, 2.78; N, 8.59. Found: C, 51.08; H, 2.99; N, 8.14. 
4.1.2.19. 2-Hydroxy-4-nitro-N-[4-nitro-3-(trifluoromethyl)phenyl]benzamide (19). 
Yellow solid; yield 69%; mp 194-195 
o
C. IR (ATR): 3406, 3120, 1667 (CO). 
1
H NMR (500 
MHz, DMSO): δ 11.68 (1H, bs, OH), 11.16 (1H, s, NH), 8.42 (1H, d, J = 1.1 Hz, H2’), 8.24 
(1H, d, J = 9.0 Hz, H5’), 8.20 (1H, dd, J = 9.0 Hz, J = 1.8 Hz, H6’), 7.90 (1H, d, J = 8.2 Hz, 
H6), 7.79-7.74 (2H, m, H3,H5). 
13C NMR (125 MHz, DMSO): δ 164.79, 156.73, 149.74, 
143.17, 141.87, 131.04, 127.66, 127.10, 123.29, 122.94 (q, J = 33.0 Hz), 122.05 (q, J = 271.5 
Hz), 118.16 (q, J = 6.0 Hz), 113.48, 111.26. Anal. Calcd for C13H8F3N3O6 (371.23): C, 45.30; 
H, 2.17; N, 11.32. Found: C, 44.72; H, 2.63; N, 10.92. 
4.1.2.20. 2-Hydroxy-4-nitro-N-(3-nitrophenyl)benzamide (20). Yellow solid; yield 63%; 
mp 221-222 
o
C. IR (ATR): 3400, 3091, 1655 (CO). 
1H NMR (500 MHz, DMSO): δ 11.77 
(1H, bs, OH), 10.85 (1H, s, NH), 8.77 (1H, s, H2’), 8.04 (1H, dd, J = 7.8 Hz, J = 1.3 Hz, 
H4’), 7.98 (1H, dd, J = 8.2 Hz, J = 2.2 Hz, H6’), 7.93 (1H, d, J = 9.3 Hz, H6), 7.80-7.73 (2H, 
m, H3,H5), 7.65 (1H, t, J = 8.2 Hz, H5’). 13C NMR (125 MHz, DMSO): δ 164.42, 156.58, 
149.58, 147.95, 139.55, 130.91, 130.22, 127.09, 126.13, 118.60, 114.23, 113.67, 111.20. 
Anal. Calcd for C13H9N3O6 (303.23): C, 51.49; H, 2.99; N, 13.86. Found: C, 50.94; H, 3.24; 
N, 13.52. 
4.1.2.21. 2-Hydroxy-4-nitro-N-(4-nitrophenyl)benzamide (21). Yellow solid; yield 61%; 
mp 253-255 
o
C. IR (ATR): 3392, 3090, 1655 (CO). 
1H NMR (500 MHz, DMSO): δ 10.90 
(1H, s, NH), 8.30-8.21 (2H, m, H3’,H5’), 8.02-7.96 (2H, m, H2’,H6’), 7.94 (1H, d, J = 8.4 
Hz, H6), 7.80-7.73 (2H, m, H3,H5). 
13C NMR (125 MHz, DMSO): δ 164.23, 156.47, 149.60, 
144.30, 142.75, 130.79, 126.86, 124.60, 119.74, 113.38, 111.11. Anal. Calcd for C13H9N3O6 
(303.23): C, 51.49; H, 2.99; N, 13.86. Found: C, 50.98; H, 3.18; N, 13.61. 
4.1.2.22. N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-4-nitrobenzamide (22). Yellow 
solid; yield 74%; mp 253-255 
o
C. IR (ATR): 3340, 3116, 1640 (CO). 
1
H NMR (300 MHz, 
DMSO): δ 11.72 (1H, bs, OH), 10.98 (1H, s, NH), 8.43 (2H, s, H2’,H6’), 7.92 (1H, d, J = 8.0 
Hz, H6), 7.83 (1H, s, H4’), 7.80-7.73 (2H, m, H3,H5). 13C NMR (75 MHz, DMSO): δ 164.69, 
156.48, 149.69, 140.36, 130.97, 130.81 (q, J = 32.3 Hz), 126.98, 123.20 (q, J = 271.5 Hz), 
119.91 (q, J = 3.75 Hz), 116.90 (q, J = 3.8 Hz), 113.71, 111.19. Anal. Calcd for C13H8F6N2O4 
(394.23): C, 45.70; H, 2.05; N, 7.11. Found: C, 45.24; H, 2.39; N, 8.89. 
4.1.2.23. 2-Hydroxy-N-(3-iodophenyl)-5-nitrobenzamide (23). White solid; yield 80%; 
mp 239-240 
o
C. IR (ATR): 3332, 3129, 1637 (CO). 
1H NMR (500 MHz, DMSO): δ 10.58 
(1H, s, NH), 8.72 (1H, d, J = 2.8 Hz, H6), 8.28 (1H, dd, J = 9.1 Hz, J = 2.8 Hz, H4), 8.20 (1H, 
s, H2’), 7.69 (1H, d, J = 8.2 Hz, H6’), 7.51 (1H, d, J = 7.8 Hz, H4’), 7.18 (1H, t, J = 10.0 Hz, 
H5’), 7.16 (1H, d, J = 10.0 Hz, H3). 13C NMR (125 MHz, DMSO): δ 164.15, 163.07, 139.45, 
139.33, 132.85, 130.79, 128.76, 128.40, 125.78, 119.88, 119.72, 117.96, 94.49. Anal. Calcd 
for C13H9IN2O4 (384.13): C, 40.65; H, 2.36; N, 7.29. Found: C, 40.11; H, 2.71; N, 6.94. 
4.1.2.24. N-(3-Bromophenyl)-2-hydroxy-5-nitrobenzamide (24). White solid; yield 
76%; mp 231-232 
o
C. IR (ATR): 3333, 3077, 1617 (CO). 
1H NMR (300 MHz, DMSO): δ 
10.64 (1H, s, NH), 8.70 (1H, d, J = 2.9 Hz, H6), 8.28 (1H, dd, J = 9.2 Hz, J = 2.9 Hz, H4), 
8.06 (1H, s, H2’), 7.65 (1H, m, H5’), 7.35 (2H, m, H4’,H6’), 7.16 (1H, d, J = 9.2 Hz, H3). 13C 
NMR (75 MHz, DMSO): δ 164.16, 162.98, 139.70, 139.36, 130.78, 128.42, 126.93, 125.85, 
  
122.91, 121.52, 119.89, 119.40, 117.95. Anal. Calcd for C13H9BrN2O4 (337.13): C, 46.32; H, 
2.69; N, 8.31. Found: C, 45.91; H, 2.97; N, 8.04. 
4.1.2.25. N-(3-Chlorophenyl)-2-hydroxy-5-nitrobenzamide (25).
32
 White solid; yield 
76%; mp 227.5-228.5 
o
C. IR (ATR): 3331, 3085, 1630 (CO). 
1H NMR (500 MHz, DMSO): δ 
10.64 (1H, s, NH), 8.71 (1H, d, J = 2.9 Hz, H6), 8.28 (1H, dd, J = 9.0 Hz, J = 2.9 Hz, H4), 
7.92 (1H, s, H2’), 7.62 (1H, m, H6’), 7.40 (1H, t, J = 8.1 Hz, H5’), 7.20 (1H, d, J = 8.2 Hz, 
H4’), 7.16 (1H, d, J = 9.1 Hz, H3). 13C NMR (125 MHz, DMSO): δ 164.14, 162.95, 139.54, 
139.36, 133.08, 130.45, 128.39, 125.84, 124.01, 120.07, 119.86, 119.01, 117.94. Anal. Calcd 
for C13H9ClN2O4 (392.68): C, 53.35; H, 3.10; N, 9.57. Found: C, 52.89; H, 3.52; N, 9.10. 
4.1.2.26. N-(3-Fluorophenyl)-2-hydroxy-5-nitrobenzamide (26).
32, 33
 White solid; yield 
73%; mp 218-219 
o
C. IR (ATR): 3333, 3085, 1612 (CO). 
1H NMR (500 MHz, DMSO): δ 
10.66 (1H, s, NH), 8.70 (1H, d, J = 2.8 Hz, H6), 8.28 (1H, dd, J = 9.1 Hz, J = 2.8 Hz, H4), 
7.71 (1H, d, J = 11.5 Hz, H2’), 7.47 (1H, d, J = 8.2 Hz, H6’), 7.41 (1H, dd, J = 15.0 Hz, J = 
8.0 Hz, H5’), 7.16 (1H, d, J = 9.1 Hz, H3), 6.98 (1H, td, J = 8.5 Hz, J = 2.4 Hz, H4’). 13C 
NMR (125 MHz, DMSO): δ 164.07, 162.88, 162.07 (d, J = 240.0 Hz), 139.81 (d, J = 11.0 
Hz), 139.38, 130.41 (d, J = 9.4 Hz), 128.36, 125.86, 119.97, 117.92, 116.32 (d, J = 2.7 Hz), 
110.78 (d, J = 21.1 Hz), 107.37 (d, J = 26.2 Hz). Anal. Calcd for C13H9FN2O4 (276.22): C, 
56.53; H, 3.28; N, 10.14. Found: C, 56.29; H, 3.61; N, 9.85. 
4.1.2.27. N-(3,4-Dichlorophenyl)-2-hydroxy-5-nitrobenzamide (27).
32, 33
 White solid; 
yield 84%; mp 273-274 
o
C. IR (ATR): 3391, 3097, 1655 (CO). 
1
H NMR (300 MHz, DMSO): 
δ 10.70 (1H, s, NH), 8.67 (1H, d, J = 2.8 Hz, H6), 8.27 (1H, dd, J = 9.2 Hz, J = 2.9 Hz, H4), 
8.09 (1H, d, J = 2.1 Hz, H2’), 7.67 (1H, dd, J = 8.8 Hz, J = 2.2 Hz, H6’), 7.61 (1H, d, J = 8.8 
Hz, H5’), 7.15 (1H, d, J = 9.0 Hz, H3). 13C NMR (75 MHz, DMSO): δ 164.13, 162.87, 
139.34, 138.26, 131.04, 130.68, 128.46, 125.91, 125.80, 121.75, 120.56, 119.92, 117.94. 
Anal. Calcd for C13H8Cl2N2O4 (327.12): C, 47.73; H, 2.47; N, 8.56. Found: C, 47.21; H, 2.78; 
N, 8.12. 
4.1.2.28. 2-Hydroxy-5-nitro-N-[3-(trifluoromethyl)phenyl]benzamide (28).
33
 White 
solid; yield 71%; mp 181-183 
o
C. IR (ATR): 3342, 3199, 1632 (CO). 
1
H NMR (500 MHz, 
DMSO): δ 10.79 (1H, s, NH), 8.73 (1H, d, J = 2.8 Hz, H6), 8.29 (1H, dd, J = 9.1 Hz, J = 2.9 
Hz, H4), 8.21 (1H, s, H2’), 7.94 (1H, d, J = 8.1 Hz, H4’), 7.62 (1H, t, J = 8.0 Hz, H5’), 7.50 
(1H, d, J = 7.7 Hz, H6’), 7.17 (1H, d, J = 9.0 Hz, H3). 13C NMR (125 MHz, DMSO): δ 
164.40, 163.03, 139.34, 138.90, 130.00, 129.49 (q, J = 31.6 Hz), 128.42, 125.83, 124.06 (q, J 
= 271.0 Hz), 124.21, 120.61 (q, J = 3.7 Hz), 119.82, 117.96, 116.73 (q, J = 4.1 Hz). Anal. 
Calcd for C14H9F3N2O4 (326.23): C, 51.54; H, 2.78; N, 8.59. Found: C, 51.08; H, 3.01; N, 
8.10. 
4.1.2.29. 2-Hydroxy-5-nitro-N-[4-(trifluoromethyl)phenyl]benzamide (29).
31
 White 
solid; yield 76%; mp 255-256 
o
C. IR (ATR): 3391, 3097, 1632 (CO). 
1
H NMR (300 MHz, 
DMSO): δ 10.79 (1H, s, NH), 8.69 (1H, d, J = 2.9 Hz, H6), 8.28 (1H, dd, J = 9.2 Hz, J = 2.9 
Hz, H4), 7.94 (2H, d, J = 8.6 Hz, H3’,H5’), 7.73 (2H, d, J = 8.7 Hz, H2’,H6’), 7.17 (1H, d, J 
= 9.2 Hz, H3). 
13C NMR (75 MHz, DMSO): δ 164.21, 162.78, 141.80, 141.79, 139.38, 
128.40, 126.07 (q, J = 3.75 Hz), 124.12 (q, J = 31.5 Hz), 122.51, 120.41, 120.26, 117.91. 
Anal. Calcd for C14H9F3N2O4 (326.23): C, 51.54; H, 2.78; N, 8.59. Found: C, 51.12; H, 3.12; 
N, 8.03. 
4.1.2.30. 2-Hydroxy-5-nitro-N-[4-nitro-3-(trifluoromethyl)phenyl]benzamide (30). 
White solid; yield 62%; mp 255-256 
o
C. IR (ATR): 3358, 3094, 1665 (CO). 
1
H NMR (500 
MHz, DMSO): δ 11.15 (1H, s, NH), 8.63 (1H, d, J = 2.9 Hz, H6), 8.42 (1H, s, H2’), 8.59 (1H, 
dd, J = 9.1 Hz, J = 2.9 Hz, H4), 8.24 (1H, d, J = 9.1 Hz, H5’), 8.22 (1H, dd, J = 9.0 Hz, J = 
1.9 Hz, H6’), 7.17 (1H, d, J = 9.2 Hz, H3). 13C NMR (125 MHz, DMSO): δ 164.70, 162.76, 
143.15, 142.14, 139.45, 128.74, 127.72, 126.27, 123.77, 122.73 (q, J = 31.3 Hz), 122.26 (q, J 
  
= 273Hz), 120.63, 118.66 (q, J = 6.25 Hz), 118.05. Anal. Calcd for C14H9F3N2O4 (371.23): C, 
45.30; H, 2.17; N, 11.32. Found: C, 44.88; H, 2.46; N, 11.01. 
4.1.2.31. 2-Hydroxy-5-nitro-N-(3-nitrophenyl)benzamide (31).
32, 34
 White solid; yield 
66%; mp 235-236 
o
C. IR (ATR): 3342, 3091, 1626 (CO). 
1H NMR (500 MHz, DMSO): δ 
10.89 (1H, s, NH), 8.74 (1H, t, J = 1.9 Hz, H2’), 8.70 (1H, d, J = 2.8 Hz, H6), 8.28 (1H, dd, J 
= 9.1 Hz, J = 2.8 Hz, H4), 8.06 (1H, d, J = 8.1 Hz, H4’), 7.99 (1H, dd, J = 8.1 Hz, J = 2.0 Hz, 
H6’), 7.66 (1H, d, J = 8.2 Hz, H5’), 7.17 (1H, d, J = 9.1 Hz, H3). 13C NMR (125 MHz, 
DMSO): δ 164.44, 162.95, 147.91, 139.32, 139.31, 130.17, 128.49, 126.50, 125.90, 119.87, 
118.73, 117.95, 114.63. Anal. Calcd for C13H9N3O6 (303.23): C, 51.49; H, 2.99; N, 13.86. 
Found: C, 51.12; H, 3.14; N, 13.55. 
4.1.2.32. 2-Hydroxy-5-nitro-N-(4-nitrophenyl)benzamide (32). White solid; yield 67%; 
mp 208-210 
o
C. IR (ATR): 3375, 3088, 1660 (CO). 
1H NMR (300 MHz, DMSO): δ 11.04 
(1H, s, NH), 8.63 (1H, d, J = 2.7 Hz, H6), 8.27 (3H, m, H4,H3’,H5’), 7.98 (2H, d, J = 9.1 Hz, 
H2’,H6’), 7.16 (1H, d, J = 9.1 Hz, H3). 13C NMR (75 MHz, DMSO): δ 164.23, 156.48, 
149.61, 144.31, 142.76, 130.79, 126.86, 124.60, 119.74, 113.38, 111.12. Anal. Calcd for 
C13H9N3O6 (303.23): C, 51.49; H, 2.99; N, 13.86. Found: C, 51.21; H, 3.21; N, 13.47. 
4.1.2.33. N-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxy-5-nitrobenzamide (33).
16
 
White solid; yield 69%; mp 223-224 
o
C. IR (ATR): 3387, 3097, 1645 (CO). 
1
H NMR (300 
MHz, DMSO): δ 11.02 (1H, s, NH), 8.69 (1H, d, J = 2.9 Hz, H6), 8.42 (2H, s, H2’,H6’), 8.28 
(1H, dd, J = 9.1 Hz, J = 2.9 Hz, H4), 7.82 (1H, s, H4’), 7.16 (1H, d, J = 9.1 Hz, H3). 13C 
NMR (75 MHz, DMSO): δ 164.64, 162.90, 140.15, 139.29, 130.73 (q, J = 32.9 Hz), 128.58, 
125.97, 125.90, 123.19 (q, J = 272.8 Hz), 120.32, 120.29, 119.78, 117.98, 117.96, 116.96 (q, 
J = 3.7 Hz). Anal. Calcd for C15H8F6N2O4 (394.23): C, 45.70; H, 2.05; N, 7.11. Found: C, 
45.24; H, 2.57; N, 6.87. 
 
4.2. Biology 
 
4.2.1 In vitro antimycobacterial evaluation 
The in vitro antimycobacterial activity of the synthesized compounds was determined 
against Mycobacterium tuberculosis My 331/88 (H37RV), M. avium My 330/80, M. kansasii 
235/80 and M. kansasii 6509/96. All strains were obtained from the Czech National 
Collection of Type Cultures (CNCTC, Brno, Czech Republic) except of M. kansasii 6509/96, 
which was clinically isolated. Basic suspensions of the mycobacterial strains were prepared 
according to a 1.0 McFarland standard. From the basic suspension, subsequent dilutions of 
each strain were made: M. tuberculosis 10
-3
, M. avium 10
-5
 and M. kansasii 10
-4
. The 
antimycobacterial activity of the compounds was determined in a Šula’s semisynthetic 
medium (SEVAC, Prague, Czech Republic) via the micromethod for the determination of the 
minimum inhibitory concentration (MIC) at 37 
o
C after 14 and 21 days and after 7, 14 and 21 
days for M. kansasii.
40
 The tested compounds were added to the medium as DMSO solutions 
while INH was used as a standard in a sterile water solution. The concentrations of the tested 
compounds were used as following: 500, 250, 125, 62.5, 32, 16, 8, 4, 2, 1 and 0.5 μM. The 
same concentrations within the range from 0.5 to 250 μM were used for INH. 
 
4.2.2 In vitro antibacterial evaluation 
The in vitro antibacterial activity was assayed against eight Gram-positive and Gram-
negative strains: Staphylococcus aureus CCM 4516/08, methicillin-resistant Staphylococcus 
aureus H 5996/08 (MRSA), Staphylococcus epidermis H 6966/08, Enterococcus aureus H 
  
6966/08, Enterococcus sp. J 14365/08, Escherichia coli CCM 4517, Klebsiella pneumoniae D 
11750/08, ESBL-positive Klebsiella pneumoniae J 14368/08, and Pseudomonas aeruginosa 
CCM 1961. 
The microdilution broth method modified according to standard M07-A07 in Mueller-
Hinton broth (HiMedia Laboratories, Mumbai, India) adjusted to pH 7.4 (±0.2) was used. The 
tested compounds were dissolved in DMSO to the final concentrations ranging from 500 to 
0.49 µmol/L. Benzylpenicillin (penicillin G) was used as a comparative drug. Bacterial 
inoculum in sterile water was prepared to match 0.5 McFarland scale (1.5 ± 10
8
 CFU/mL). 
The minimum inhibitory concentrations were assayed as 95% (IC95) or higher reduction of 
growth when compared to the control. The determination of results was performed visually 
and spectrophotometrically (at 540 nm). The values of MICs were determined after 24 and 48 
h of incubation in the darkness at 35 
o
C (±0.1) in a humid atmosphere. 
 
4.2.3 In vitro antifungal evaluation 
The antifungal properties were evaluated in vitro against four Candida strains (Candida 
albicans ATCC 44859, Candida tropicalis 156, Candida krusei E28, and Candida glabrata 
20/I), Trichosporon asahii 1188 and three filamentous fungi (Aspergillus fumigatus 231, 
Absidia corymbifera 272, and Trichophyton mentagrophytes 445). The microdilution broth 
method was used according to the CLSI M27-A3 and M38-A2 guidelines in RPMI 1640 with 
glutamine (KlinLab, Prague, Czech Republic) buffered to pH 7.0 with 0.165 mol of 3-
morpholino-propane-1-sulphonic acid (Sigma-Aldrich, Darmstadt, Germany). DMSO served 
as a diluent for all of the compounds. In yeast, the final size of the inoculum was 5 x 10
3
 ± 0.2 
CFU/mL. In the case of the moulds Aspergillus, Trichophyton and Absidia corymbifera, the 
spores were harvested after cultivation of a given fungal strain grown on Sabouraud agar from 
3 to 10 days. The final size of the inoculum was 0.5–5 x 104 CFU/mL. The sizes of the fungal 
inocula were checked using a Bürker chamber. Fluconazole was used as a reference drug. The 
MIC values for yeasts and filamentous fungi were assayed as a reduction of growth of at least 
80% (IC80) or of at least 50% (IC50) compared with the control, respectively. The results were 
analyzed visually and spectrophotometrically (at 540 nm). The MIC values were determined 
after 24 and 48 h of incubation in the dark at 35 
o
C (±0.1) in a humid atmosphere, but for T. 
mentagrophytes, the final MIC values were determined after 72 and 120 h of incubation. 
 
4.2.4 Cytotoxicity 
Twelve nitrosalicylanilides, selected depending on the position of their nitro-substitution 
and their antimycobacterial activity, were tested for cytotoxicity in the human hepatocellular 
liver carcinoma cell line HepG2 (passages 33-37; ECACC, Salisbury, UK) using a standard 
colorimetric method measuring a tetrazolium salt reduction (CellTiter(R) 96 AQueous One 
Solution Assay, Promega G3580, Madison, WI, USA). 
The cells were routinely cultured in Minimum Essentials Eagle Medium (Sigma-Aldrich, 
Darmstadt, Germany) supplemented with 10% fetal bovine serum (PAA, Biotech, Prague, 
Czech Republic), 1% of L-glutamine solution (Sigma-Aldrich), and non-essential amino acids 
solution (Sigma-Aldrich) in a humidified atmosphere containing 5% CO2 at 37 
o
C. For 
subculturing, the cells were harvested after trypsin/EDTA (Sigma-Aldrich) treatment at 37 
o
C. 
The cells treated with the tested substances were used as experimental groups. Untreated 
HepG2 cells were used as control groups. 
The cells were seeded in density 1 x 10
4
 cells per well in a 96-well plate with microscopic 
control. Next day, the cells were treated with each of the tested substances. All tested 
  
substances were prepared at concentrations 0.1-100 μM and tested in triplicates. The 
following types of controls were included: determination of 100% viability and 0% viability 
(the cells treated by 10% DMSO), no cell control and vehiculum controls. These checking 
samples were prepared in triplicates. 
The treated cells were incubated together with controls at 37 
o
C for 24 h in 5% CO2 
atmosphere. After this time reagent from the kit CellTiter 96 AQueous One Solution Cell 
Proliferation Assay was added. The CellTiter 96 assay is based on the reduction of 
tetrazolium salt MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium] to water-soluble formazan dye by metabolically active cells. 
The reduction of the reagent is attributed to availability of NADH or NADPH. The decline in 
levels of these metabolically important compounds in the cell causes that the production of 
formazan is reduced. The tested plate was incubated for 2 h at 37 
o
C and 5% CO2 and after 
this time, the absorbance was recorded at 490 nm using a 96-well plate reader (TECAN, 
Infinite M200, Grödig, Austria). 
The results were expressed as inhibitory concentration which is necessary to inhibit cell 
viability to 50% from the maximal (control) viability (IC50). A standard toxicological 
parameter IC50 was calculated in each of the tested substances using GraphPad Prism software 
(version 6; GraphPad Software Inc. San Diego, CA, USA). 
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